Floatz logo

CETIRIZINE

Infusion Reaction

Providence Health & ServicesSmall moleculePhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Infusion Reaction cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4BBB
Benadryl
Providence Health & Services
Phase 3B
Miglustat
University of Florida
Phase 1CC

Same molecule, other indications

CETIRIZINE is also rated in:

relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
64 / 100
View asset →
Fabry diseaseDormant
BB
Indicative ·
64 / 100
View asset →
type 2 diabetes mellitusDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →